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Scatter Artifact with Ga-68-PSMA-11 PET:
Severity Reduced With Furosemide
Diuresis and Improved Scatter Correction
Courtney Lawhn-Heath, MD1 , Robert R. Flavell, MD, PhD1,
David E. Korenchan, PhD1 , Timothy Deller, MSEE2, Spencer Lake, MD1,
Peter R. Carroll, MD, MPH3, and Thomas A. Hope, MD1,4
Abstract
Purpose: To assess the utility of furosemide diuresis and the role of an improved scatter correction algorithm in reducing scatter
artifact severity on Ga-68- Prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET).
Materials and Methods: A total of 139 patients underwent Ga-68-PSMA-11 PET imaging for prostate cancer: 47 non-time-of-
flight (non-TOF) PET/computed tomography, 51 PET/magnetic resonance imaging (MRI) using the standard TOF scatter cor-
rection algorithm, and 41 PET/MRI using an improved TOF scatter correction algorithm. Whole-body PET acquisitions were
subdivided into 3 regions: around kidneys; between kidneys and bladder; and around bladder. The images were reviewed, and
scatter artifact severity was rated using a Likert-type scale.
Results: The worst scatter occurred when using non-TOF scatter correction without furosemide, where 42.1% of patients
demonstrated severe scatter artifacts in 1 or more regions. Improved TOF scatter correction resulted in the smallest percentage
of studies with severe scatter (6.5%). Scatter ratings by region were lowest using improved TOF scatter correction. Furosemide
reduced mean scatter severity when using non-TOF and standard TOF.
Conclusions: Both furosemide and scatter correction algorithm play a role in reducing scatter in PSMA PET. Improved TOF
scatter correction resulted in the lowest scatter severity.
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Introduction
Prostate-specific membrane antigen (PSMA) positron emission
tomography (PET) using Ga-68-PSMA-11 is a highly sensitive
and specific imaging technique for prostate cancer.1-4 The
Ga-68-PSMA-11 demonstrates a high target-to-background
ratio and prominent renal excretion.5 Furthermore, PSMA
inhibitors such as Ga-68-PSMA-11 are retained in the kidney
cortex. This combination of characteristics leads to high levels
of activity in the urinary system (kidneys, ureters, and bladder),
which may limit sensitivity for detection of lower levels of
abnormal activity in surrounding structures, including retroper-
itoneal and pelvic lymph nodes, which are common sites of
metastatic prostate cancer. Similarly, scatter correction algo-
rithms used in PET image reconstruction can result in photo-
penic regions around the urinary system, potentially lowering
sensitivity or interfering with an accurate image interpretation.1
The severity of this artifact varies with acquisition method,
with time-of-flight (TOF) acquisition generally considered
superior to earlier non-TOF methods.6,7
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Furosemide (Lasix) administration has demonstrated efficacy
in improving overall image quality and lesion detectability in
PET using renally excreted radiotracers, including Ga-68-
PSMA-11.5,8,9 A recent study using furosemide with Ga-68-
PSMA-11 demonstrated improved image quality and lesion
detection with the use of delayed furosemide administration after
radiotracer administration.8 However, scatter correction artifact
in Ga-68-PSMA-11 PET imaging has not yet been evaluated.
The aim of this study was to assess the usefulness of furo-
semide diuresis and the role of an improved scatter correction
algorithm in reducing scatter artifact severity.
Materials and Methods
Setting and Participant Selection
A subset of patients enrolled in a prospective trial of Ga-68-
PSMA-11 (NCT02611882) evaluating Ga-68-PSMA-11 for the
detection of prostate cancer were retrospectively analyzed as
part of this study. All patients provided informed consent, and
these studies were approved by the local institution review
board. The study included patients with newly diagnosed or
biochemically recurrent prostate cancer who underwent a
whole-body Ga-68-PSMA-11 PET using either PET/computed
tomography (CT; Discovery VCT, GE Healthcare, Waukesha,
Wisconsin) or PET/ magnetic resonance imaging (MRI; Signa
3.0 T TOF PET/MRI; GE Healthcare) at University of Califor-
nia–San Francisco.
Imaging Protocols and Image Reconstruction
Ga-68-PSMA-11 was prepared as described previously using
an ITG germanium-gallium generator and an iQs fluidic label-
ing module (ITG, Ga¨rching/Munich, Germany).10 111-259
MBq (3-7 mCi) of Ga-68-PSMA-11 was injected intrave-
nously. In a subset of cases, a dose of 20 mg of furosemide
was injected together with the administration of the radiotracer.
Reasons for not administering furosemide included allergy,
hypotension, patient refusal, and technical/nursing error. In all
cases, patients were encouraged to void prior to imaging.
Patients were scanned with PET/CT (Discovery VCT, GE
Healthcare) or PET/MRI (3.0 T TOF Signa PET/MRI; GE
Healthcare). On average, PET imaging began 68.4 minutes
(range 45-162, standard deviation [SD]16.1) after injection. For
PET/CT, the pelvis to vertex was imaged using a 5-minute
acquisition per bed position from the pelvis through the mid-
abdomen and 3-minute acquisitions from the upper abdomen to
the vertex. Iodinated contrast was administered to all patients,
unless contraindicated. A postcontrast diagnostic CT was then
obtained and used for attenuation correction (mA ¼ 240, kV ¼
120, slice thickness ¼ 2 mm). PET data were reconstructed
using iterative reconstruction with 4 iterations and 14 subsets
and a matrix size of 168 168. The PET transaxial field of view
was 620 mm, and axial slice thickness was 5.0 mm.
For PET/MRI, a pelvis and abdomen bed position was
imaged using an 8-minute acquisition. The PET data were
reconstructed using TOF, Ordered Subset Expectation Maxi-
mization (OSEM) using 2 iterations and 28 subsets and a
matrix size of 256  256, with a 600  250 mm field of view
and a 2.8 mm slice thickness. A dynamic contrast-enhanced
sequence was acquired of the pelvis after the administration of
gadolinium, followed by T2-weighted, diffusion-weighted, and
a post-gadolinium delayed axial T1-weighted imaging. For the
whole-body acquisition, PET data were acquired for 3 minutes
at each bed position with axial T1- and T2-weighted sequences
in the coronal and axial plane. Attenuation correction was per-
formed as described previously11 with a standard 2-point Dixon
acquisition converted into an attenuation map.
On PET/CT, patients were imaged with the arms up if
tolerated. If a patient was unable to tolerate this positioning
due to pain or other discomfort, the patient was imaged with 1
or both arms down. On PET/MRI, patient’s arms are imaged
with their arms down. This is standard on all PET/MRI studies,
as the arms do not create streak artifact that can be limiting in
PET/CT. It is more comfortable for the patient and does not
interfere with MR image quality.
Scatter Correction Algorithm
Standard scatter correction algorithms were developed for F-18
tracers and tend to overestimate scatter in areas of high uptake
using Ga-68-labeled tracers such as PSMA and somatostatin
receptor agents due to higher target to background ratios.
Developing an improved algorithm involved modifying multi-
ple parameters that were originally developed in the setting of
fluorodeoxyglucose-PET.12 For more accurate scatter estima-
tion using Ga-68 PET, the number of axial subsamples was
increased. To compensate for the resultant increased compu-
tational load, the image grid was downsampled in the coronal
and sagittal planes. Standard scatter tails were modified by a
factor determined by a least squares fit for each plane and then
axially smoothed. A factor taking into account the prompt g
associated with Ga-68 was also added to the model. Standard
scatter correction algorithms do not incorporate this factor
because 18-F does not have a prompt g phenomenon. This
resultant improved scatter correction algorithm has recently
been described in detail.13 Figure 1 shows the same patient
scanned using standard TOF (A-C) and improved TOF (D-F)
scatter correction.
Imaging Data Collection and Analysis
The whole-body PET images for each study were reviewed by
2 readers (CL and SL) on a PACS workstation (Agfa Health-
care, Mortsel, Belgium). The PET images were evaluated for
the presence of scatter artifact within the abdomen/pelvis at 3
levels: kidneys, between kidneys and bladder, and bladder.
Scatter artifact severity at each level was rated using a
Likert-type scale as follows: 1 ¼ none; 2 ¼ mild, involving a
small to medium region, unlikely to hinder diagnosis; 3 ¼
moderate, involving a large region; 4 ¼ severe, dense artifact
over a small to medium region, likely to obscure small lesions;
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and 5¼ very severe, dense artifact over a large region, likely to
obscure large lesions (Figure 2). The PET images were scaled
to accentuate the artifact seen. The ratings from both reviewers
were averaged to arrive at a final mean artifact severity rating
per level. On a dedicated workstation using Advanced Work-
station for Diagnostic Imaging (GE Healthcare), Maximum
Standardized Uptake Value (SUVmax) was measured at the
kidneys, bladder, and background using volumes of interest
measuring at least 20 mm in diameter. Background SUVmax
was measured at the right thigh.
A retrospective chart review was performed in an electronic
medical record system, and demographic data were collected
for each study, including patient age, height, weight, and Pros-
tate-Specific Antigen (PSA) level; imaging modality (PET/CT
vs. PET/MRI); time and dose of radiotracer administration;
time and dose of furosemide administration (if given); and start
time of PET acquisition.
Statistical Analysis
Interrater reliability was evaluated using Cohen k. Statistical
analysis was performed using R version 3.3.3. Differences in
mean scatter severity by body mass index (BMI) and by scan
delay time were compared using t tests. Standard deviation and
error as well as t tests were calculated, and figures were con-
structed using Microsoft Excel 2011 for Mac. Linear regression
between mean scatter artifact score and maximum SUVwas per-
formed in MATLAB (Mathworks, Natick, Massachusetts). Sta-
tistically significant correlations were identified using a 2-tailed
nonparametric Spearman rank correlation coefficient test.
Figure 1. Coronal (A and B, D and E) and axial (C and F) Ga-68-PSMA-11 positron emission tomography (PET) images of the same patient with
standard time-of-flight (TOF) scatter correction (A-C) and improved TOF scatter correction (D-F), demonstrating marked reduction in scatter
artifact with improved TOF.
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Results
A total of 139 patients were evaluated. Forty-seven patients
underwent non-TOF PET/CT of which 28 received furosemide;
51 patients underwent PET/MRI with a standard TOF scatter
correction algorithm of which 36 received furosemide; and 41
patients underwent PET/MRI with an improved TOF scatter
correction algorithm of which 34 received furosemide
(Table 1). Of note, the time between radiotracer administration
and scanning was similar between non-TOF PET/CT
(63.1 minutes, SD 11.2 minutes) and standard TOF PET/MRI
(62.1 minutes, SD 5.9 minutes) but was longer with improved
TOF PET/MRI (82.8 minutes, SD 20.5 min).
Subjective Scatter Ratings
Interrater agreement was moderate at all regions evaluated
(kvalues: kidneys ¼ 0.44, between kidneys and bladder ¼
0.49, and bladder ¼ 0.49). Score distributions of the individual
raters are shown in Figure 3. The worst scatter artifact occurred
when using non-TOF scatter correction without furosemide,
where 42.1% of studies demonstrated severe4 or very severe5
scatter artifacts in 1 or more regions, compared to 21.4% with
furosemide (Figure 4A). Improved TOF resulted in the lowest
percentage of studies with severe scatter at 1 or more regions,
0% to 6.2% compared to 22.2% to 33.3% with standard TOF
and 21.4% to 42.1% with non-TOF (Figure 4A). Improved
TOF also resulted in the lowest percentage of studies with
severe scatter at each evaluated region (Figure 4B-D). Mean
scatter severity ratings were lowest in all 3 evaluated regions
with improved TOF scatter correction, which resulted in very
little scatter artifact overall (Figure 5A-C). Within a given
scatter correction algorithm, furosemide administration
resulted in lower mean scatter ratings with non-TOF and stan-
dard TOF but not with improved TOF (Figure 5A-C). Taking
all acquisitions as a whole, longer scan delay times (90þ min-
utes) were associated with a small but statistically significant
improvement in mean scatter severity ratings compared to
shorter delay times (<90 minutes; mean scatter ratings of 1.6
and 1.3, respectively; P < .01; Table 2). In addition, BMI of
30þ (obese) resulted in a small but statistically significant
increase in scatter artifact compared to patients with BMI
<30 (1.8 and 1.6, respectively; P < .01; Table 3).
Figure 2. Scatter rating examples. Scatter artifact severity at each level was rated using a Likert-type scale as follows: 1 - none; 2 - mild, involving
a small to medium region, unlikely to hinder diagnosis; 3 - moderate, involving a large region; 4 - severe, dense artifact over a small to medium
region, likely to obscure small lesions; and 5 - very severe, dense artifact over a large region, likely to obscure large lesions.
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Renal and Bladder Activity on Ga-68-PSMA PET
Overall, higher bladder SUVmax and similar renal SUVmax
were seen on both standard and improved TOF scatter algo-
rithms compared to non-TOF (Figure 6A-C), although mean
scatter severity was lower than on non-TOF. Administering
furosemide was associated with lower renal and bladder SUV-
max on non-TOF and lower bladder SUVmax on standard TOF
(Figure 6A and B) but was not associated with a notable dif-
ference in SUVmax on improved TOF or at the kidneys on
standard TOF (Figure 6B and C). Regression analysis demon-
strated a statistically significant positive correlation between
SUVmax and scatter severity rating at the levels of the kidneys
(Supplemental Figure 1) for non-TOF imaging only (P < .002)
but no other significant correlation between SUVmax and
scatter severity.
Discussion
Scatter artifact, also known as halo artifact, washout artifact, or
photopenic artifact, is a common occurrence with Ga-68-
PSMA PET and may interfere with lesion detectability.14-19
In this study, we evaluated the effect of both furosemide
administration and scatter correction algorithm on subjective
image quality by comparing the mean scatter severity rating of
Ga-68-PSMA-11 non-TOF and TOF acquisitions. Overall scat-
ter ratings were lowest using improved TOF scatter correction,
regardless of furosemide administration and overall higher
renal and bladder uptake. The TOF acquisition without
improved scatter correction resulted in lower artifact than on
non-TOF. The worst scatter artifact was seen with non-TOF,
for which furosemide administration demonstrated a reduction
in scatter severity in all 3 evaluated regions.
For non-TOF and standard TOF scatter correction algo-
rithms, the results of our study agree with previous literature
that furosemide diuresis is helpful in improving image quality.8
In our study, furosemide administration did not significantly
affect scatter severity when using improved scatter correction,
although this may be due to a very low overall presence of
scatter artifact compared to standard TOF and non-TOF. As
such, our data suggest that furosemide administration is helpful
with scanners using non-TOF and standard TOF scatter correc-
tion algorithms but may not be necessary when using an
improved TOF algorithm.
Recent literature suggests that numerous factors appear to
contribute to scatter artifact. Timing of image acquisition rela-
tive to radiotracer injection may play a role, although some
studies favor early acquisition at approximately 1 hour post-
injection (p.i.),20,21 and others favor late acquisition at approx-
imately 3 hours p.i.18,22 The first joint European Association of
Nuclear Medicine (EANM) and Society of Nuclear Medicine
and Molecular Imaging (SNMMI) PSMA imaging guidelines
recommend early imaging (50-100 minutes p.i.), citing advan-
tages in both workflow practicality and residual activity of the
radiotracer, given its shorter half-life.16 In our study, although
the improved TOF group was imaged later than the other
groups, the time difference was much smaller than the 2-hour
time difference between “early” and “late” imaging in the pre-
viously mentioned studies and is therefore unlikely to have had
a significant effect on the reduction of scatter artifact observed
in the improved TOF group. In addition, mean activity in the
kidneys and bladder was similar between standard TOF and
Table 1. Characteristics of the Study Population.a
Non-TOF
Standard
TOF
Improved
TOF
# Participants, total 47 51 41
furosemide 19 15 7
þ furosemide 28 36 34
Age, years, total (SD) 67.9 (8.5) 67.7 (7.0) 68.4 (6.9)
furosemide 67.3 (7.6) 65.7 (7.4) 71.7 (5.3)
þ furosemide 68.2 (9.2) 68.6 (6.7) 68.4 (7.1)
Body mass index (BMI),
total (SD)
27.3 (4.6) 26.1 (3.0) 27.3 (4.2)
furosemide 27.7 (4.6) 25.5 (2.4) 26.1 (3.6)
þ furosemide 27.1 (4.7) 26.4 (3.2) 27.6 (4.3)
Height, cm, total (SD) 179.9 (7.5) 177.7 (6.1) 177.5 (7.1)
furosemide 179.4 (8.5) 176.9 (7.2) 180.2 (8.2)
þ furosemide 180.2 (6.7) 178.1 (5.6) 176.9 (6.8)
Weight, kg, total (SD) 88.5 (16.1) 82.4 (10.7) 86.3 (14.4)
furosemide 89.3 (14.6) 79.5 (7.0) 84.8 (14.4)
þ furosemide 88.2 (17.4) 83.7 (11.8) 86.1 (14.6)
PSA, ng/mL, total (SD) 12.0 (16.1) 9.8 (13.1) 11.0 (16.8)
furosemide 13.6 (9.9) 9.8 (11.5) 13.9 (17.9)
þ furosemide 8.4 (19.1) 11.7 (13.8) 10.6 (16.8)
Tracer dose, mCi, total (SD) 5.6 (1.2) 5.3 (0.8) 6.4 (0.9)
furosemide 5.3 (0.6) 5.4 (0.6) 6.2 (0.8)
þ furosemide 6.1 (1.4) 5.1 (0.9) 6.4 (0.9)
Scan delay, minutes, total (SD) 63 (11.3) 62 (5.9) 82.8 (20.5)
furosemide 61 (6.2) 64 (5.0) 80 (7.2)
þ furosemide 65 (13.6) 60 (6.0) 80 (22.4)
Abbreviations: SD, standard deviation; TOF, time-of-flight.
aContinuous variables are expressed as mean (standard deviation).
Figure 3. Scatter score distribution by rater for all 3 evaluated
regions combined.
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Figure 4. Percentage of studies with severe scatter artifact (mean scatter artifact rating of 4 [severe] or 5 [very severe]) broken down by
region. The use of furosemide and an improved scatter algorithm resulted in a smaller percentage of studies with severe scatter artifact in any
region (A), and specifically around the kidneys (B), between the kidneys and bladder (C) and around the bladder (D).
Figure 5. Mean scatter severity rating by scatter correction algorithm (non- time-of-flight [TOF], standard TOF, and improved TOF) without
() versus with (þ) furosemide administration. Improved TOF resulted in the lowest mean scatter severity ratings around the kidneys (A),
between kidneys and bladder (B), and around bladder (C). Furosemide administration reduced scatter severity with non-TOF and standard TOF
but not for improved TOF. (error bars ¼ standard error. * P < .05).
Table 2. Mean Scatter Severity Rating and Scan Delay by region.a
Scan Delay
<90 min
Scan Delay
90þ min
Mean scatter severity
Around kidneys 2.0 1.7
Between kidneys and bladderb 1.6 1.1
Around bladder 1.3 1.3
Overallb 1.6 1.3
aLonger delays in scanning after radiotracer administration (90þ minutes)
resulted in less severe scatter than shorter delays (< 90 minutes), a difference
that was statistically significant between the kidneys and bladder as well as
overall (P < .05, indicated by an asterisk), and trended toward significance
around the kidneys (P ¼ .067).
bP < .05.
Table 3. Mean Scatter Severity Rating and BMI by Region.a
BMI <30 BMI ¼ 30þ
Mean scatter severity
Around kidneysb 1.9 2.3
Between kidneys and bladderb 1.5 1.9
Around bladder 1.3 1.3
Overallb 1.6 1.8
aObese patients (BMI ¼ 30þ) had more severe scatter artifact than nonobese
patients (BMI < 30), a difference that was statistically significant around the
kidneys, between kidneys and bladder, and overall.
bP < .05.
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improved TOF groups with similar minimal background
uptake, despite the difference in scan delay between the groups.
As described in the results section, we found a small but sta-
tistically significant improvement in scatter severity ratings
overall when imaging at 90þ minutes as opposed to under
90 minutes (Table 2).
A recent study also found that a shorter acquisition time per
bed of under 180 seconds was associated with increased scatter
artifact.19 In our study, we imaged for 300 seconds per bed
position through the pelvis and abdomen and 180 seconds per
bed position from the chest through the vertex. In addition, the
arms have been observed to interfere with accurate scatter
correction,15,19 and at least 1 study17 showed decreased lesion
detectability with the arms down. Accordingly, the EANM/
SNMMI PSMA guidelines recommend imaging with the arms
up.16 In our study, all PET/MRI patients were imaged with their
arms down, which did not appear to worsen scatter artifact in
the PET/MRI studies.
Increased object-to-background uptake ratio (OBR) has
been speculated to play a role in scatter artifact,14-16 with at
least 1 study22 demonstrating a positive correlation between
OBR and halo size. However, another recent study17 found
no correlation between high bladder activity and the occurrence
or severity of scatter artifact, and another study21 found no
difference in lesion detection rates with higher OBR. Never-
theless, administering furosemide to decrease OBR in the urin-
ary system prior to imaging is a commonly advocated practice
and is discussed (though not unequivocally recommended) in
the EANM/SNMMI PSMA guidelines16 and several recent
studies18,22 One study8 demonstrated increased image quality
with the use of furosemide. However, furosemide administra-
tion is not entirely without risks. Patients may experience an
allergic reaction, an adverse drug reaction, or urinary urgency,
particularly in the setting of benign prostatic hyperplasia, a
common condition in this patient population which can result
in difficulty voiding and incomplete voiding. The latter prob-
lem could theoretically be avoided by Foley catheterization,
but this carries the additional risk of urethral injury and infec-
tion. In our study, overall scatter artifact severity was not
significantly different when using improved TOF scatter cor-
rection, regardless of furosemide administration. The results of
our study suggest that furosemide may be useful for scanners
employing non-TOF and standard TOF scatter correction but
may not be necessary when an improved TOF algorithm is
used. This suggests that despite many contributing factors, the
key determinant of the presence or absence of scatter artifact is
likely the scatter correction algorithm itself. The role of scatter
correction algorithm in reducing halo artifact and improving
image quality is discussed in several recent studies.12-14,16-18,23
The TOF is known to produce improved target to noise ratios
and subjective image quality7 and to produce less scatter
artifact (although not eliminate it entirely).15 Additional
modifications specifically for Ga-68, including prompt g
correction13,14,19 and tail fitting modifications,13,15,19 have
been shown to further improve image quality. By demon-
strating decreased scatter artifact severity using an improved
TOF algorithm, our study is complementary to these other
recent studies.
Limitations
A possible confounding factor in our study was the difference
between the study groups in delay between radiotracer admin-
istration and scan start time. While non-TOF and standard TOF
scan delays were similar with a mean of 62.1 and 63.1 minutes,
mean improved TOF scan delay was 82.8 minutes. Thus, it is
slightly less clear whether the improvement in scatter demon-
strated by the improved TOF scatter correction was entirely
due to the algorithm itself and not also a longer scan delay.
However, as discussed earlier, renal and bladder SUVmax were
similar on both standard TOF and improved TOF, despite
improved scatter with improved TOF.
Another limitation is the lack of internal controls. A more
direct comparison between scatter reduction algorithms would
have involved reconstructing the same data sets with and with-
out TOF, as well as with and without improved TOF scatter
correction, rather than scanning different patients using the
different algorithms. However, this was a retrospective study,
Figure 6.Mean SUVmax measured at kidneys and bladder without () and with (þ) furosemide administration by scatter correction algorithm:
non-time-of-flight (TOF; A), standard TOF (B), and improved TOF (C). Despite overall lower scatter severity, mean SUVmax was at least as high
with improved TOF as with non-TOF and standard TOF. Error bars ¼ standard error.
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and the overall patient characteristics did not vary widely
between the groups.
In addition, furosemide administration was not randomized,
which may introduce and element of bias. The reasons patients
did not receive furosemide included allergy, hypotension,
patient refusal, and technical/nursing error. However, Table 1
demonstrates that the groups who received furosemide were
similar to those who did not receive furosemide.
Conclusion
Both furosemide and scatter correction algorithm type play a
role in reducing scatter in PSMA PET. Improved TOF scatter
correction resulted in the lowest scatter artifact severity and
almost no severe scatter artifact, regardless of furosemide
administration. Furosemide administration was associated with
lower scatter severity when using non-TOF and standard TOF
scatter correction.
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